# Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD

> **NCT02847624** · — · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 1802 (actual)

## Conditions studied

- Polycystic Kidney, Autosomal Dominant

## Interventions

- **DRUG:** tolvaptan

## Key facts

- **NCT ID:** NCT02847624
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-24
- **Primary completion:** 2022-09-20
- **Final completion:** 2022-09-20
- **Target enrollment:** 1802 (ACTUAL)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02847624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02847624, "Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02847624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*